Comparative Pharmacology
Head-to-head clinical analysis: NEOSPORIN versus SSD AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSPORIN versus SSD AF.
NEOSPORIN vs SSD AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
Apply a thin layer topically once or twice daily to affected area.
None Documented
None Documented
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients.
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic